Anneka Tomlinson

Anneka Tomlinson

Auto-generated profile, based on publicly available information

Anneka Tomlinson

Department of Psychiatry, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
ATAnneka Tomlinson
Anneka Tomlinson
BGBen Grayson
Ben Grayson
SMSamuel Marsh
Samuel Marsh
MHMichael Harte
Michael Harte
SBSamuel A. Barnes
Samuel A. Barnes
JNJoanna C. Neill
Joanna C. Neill

1 April 2015 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
ATAnneka Tomlinson
Anneka Tomlinson
BGBen Grayson
Ben Grayson
SMSamuel Marsh
Samuel Marsh
AHAndrew Hayward
Andrew Hayward
KMKay M Marshall
Kay M Marshall
JNJoanna C Neill
Joanna C Neill

1 February 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
AHAndrew Hayward
Andrew Hayward
ATAnneka Tomlinson
Anneka Tomlinson
JNJoanna C. Neill
Joanna C. Neill

1 August 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
GGGeorge Gillett
George Gillett
ATAnneka Tomlinson
Anneka Tomlinson
OEOrestis Efthimiou
Orestis Efthimiou
ACAndrea Cipriani
Andrea Cipriani

17 April 2019 in Evidence Based Mental Health
Verified
Journal Article
Open access
PDF file
ATAnneka Tomlinson
Anneka Tomlinson
OEOrestis Efthimiou
Orestis Efthimiou
KBKatharine Boaden
Katharine Boaden
ENEmma New
Emma New
SMSarah Mather
Sarah Mather
ACAndrea Cipriani
Andrea Cipriani
Introduction We have recently compared all second-generation as well as selected first-generation antidepressants in terms of efficacy and acceptability in the acute treatment of major depression. Here we present a protocol for a network meta-analysis aimed at extending these results, updating the evidence base and comparing all second-generation as well as selected first-generation antidepressants in terms of specific adverse events and tolerability in the acute treatment of major depression in adults. Methods and analysis We will include all double-blind randomised controlled trials comparing one active drug with another or with placebo in the acute treatment major depression in adults. We will compare the following active agents: agomelatine, amitriptyline, bupropion, citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine. The main outcomes will include the total number of patients experiencing specific adverse events; experiencing serious adverse events; and experiencing at least one adverse event. Published and unpublished studies will be retrieved through relevant database searches, trial registries and websites; reference selection and data extraction will be completed by at least two independent reviewers. For each outcome we will undertake a network meta-analysis to synthesise all evidence. We will use local and global methods to evaluate consistency. We will perform all analyses in R. We will assess the quality of evidence contributing to network estimates with the Confidence in Network Meta-Analysis web application. Discussion This work will provide an in- depth analysis and an insight into the specific adverse events of individual antidepressants. Ethics and dissemination This review does not require ethical approval. PROSPERO registration number CRD42019128141.

1 February 2019 in Journal of the American Academy of Child & Adolescent Psychiatry
Verified
Journal Article
Open access
SCSamuele Cortese
Samuele Cortese
ATAnneka Tomlinson
Anneka Tomlinson
ACAndrea Cipriani
Andrea Cipriani
Network meta-analyses (NMAs) are gaining traction as the preferred method for evidence synthesis of intervention studies. This review aimed to summarize the basics of NMAs and conduct a meta-review of available NMAs on the treatment of child and adolescent psychiatric disorders by appraising their quality. PubMed (Medline), PsycInfo, Embase, Ovid Medline, and Web of Knowledge were systematically searched (last update January 9, 2018). The quality of each included NMA was appraised using the AMSTAR-2 tool and the PRISMA-NMA checklist, which includes specific items for NMAs. Eighteen NMAs (6 on attention-deficit/hyperactivity disorder; 4 on psychotic disorders; 2 on depression; 2 on anxiety disorders; 1 on obsessive-compulsive disorder; 1 on disruptive behavior disorder, 1 on bipolar disorder, and 1 on antipsychotics across disorders) were retrieved. Results from the AMSTAR-2 assessment showed that only 27% of appraised NMAs were rated as moderate quality; most were rated as low (33%) or critically low (40%) quality. Only 3 of the appraised NMAs reported on all PRISMA-NMA items specific for NMAs; the network structure was graphically presented in most NMAs (80%), and inconsistency was described in only 47%. Given the paucity of head-to-head trials in child and adolescent psychiatry, NMAs have the potential to contribute to the field, because they provide evidence-based hierarchies for treatment decision making, even in the absence of trials directly comparing at least 2 treatments. However, because of important limitations in the included NMAs, additional methodologically sound NMAs are needed to inform future guidelines and clinical practice in child and adolescent psychiatry.